BioSpace

City’s IPO soars to $200M, with proceeds supporting thromboembolic disease pipeline

City Therapeutics will join a slew of biotechs that have entered the public markets this year, with a $200 million raise that landed above expectations.

By BioSpace

1 min read
City’s IPO soars to $200M, with proceeds supporting thromboembolic disease pipeline
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights